



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 1 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 1. Identification

**GHS product identifier** : Levoleucovorin for Injection

**Other means of identification** : Not available.

**Product type** : Powder.

### Relevant identified uses of the substance or mixture and uses advised against

**Product use** : Pharmaceuticals (For intended use only.).  
Observe technical data sheet/instructions for use.  
Specific Treatments: Cancer.

**Area of application** : Professional applications.

Uses advised against	Reason
Anemia	

**Supplier's details** : Meitheal Pharmaceuticals, Inc.  
8700 W. Bryn Mawr, Suite 600S  
Chicago, IL 60631

Telephone: 224-443-4617  
[www.meithealpharma.com](http://www.meithealpharma.com)

**e-mail address of person responsible for this SDS** : [info@meithealpharma.com](mailto:info@meithealpharma.com)

**Emergency telephone number (with hours of operation)** : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

## Section 2. Hazards identification

**OSHA/HCS status** : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

**Classification of the substance or mixture** : COMBUSTIBLE DUSTS  
H315 SKIN IRRITATION - Category 2  
H319 EYE IRRITATION - Category 2A  
H334 RESPIRATORY SENSITIZATION - Category 1  
H317 SKIN SENSITIZATION - Category 1  
H335 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE)  
(Respiratory tract irritation) - Category 3

### GHS label elements

<b>SDS Title:</b> Levoleucovorin for Injection Safety Data Sheet	<b>SDS Number:</b> SDS-000031	<b>Page Number:</b> Page 2 of 16
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 20, 2023	<b>Version number:</b> 3.0

## Section 2. Hazards identification

### Hazard pictograms :



### Signal word

: Danger

### Hazard statements

- : H315 - Causes skin irritation.
- H317 - May cause an allergic skin reaction.
- H319 - Causes serious eye irritation.
- H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- H335 - May cause respiratory irritation.
- May form combustible dust concentrations in air.

### Precautionary statements

#### Prevention

- : P280 - Wear protective gloves. Wear eye or face protection.
- P284 - Wear respiratory protection.
- P271 - Use only outdoors or in a well-ventilated area.
- P261 - Avoid breathing dust or mist.
- P264 - Wash thoroughly after handling.
- P272 - Contaminated work clothing must not be allowed out of the workplace.

#### Response

- : P304 + P340, P312 - IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or doctor if you feel unwell.
- P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTER or doctor.
- P362 + P364 - Take off contaminated clothing and wash it before reuse.
- P363 - Wash contaminated clothing before reuse.
- P302 + P352 - IF ON SKIN: Wash with plenty of water.
- P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention.
- P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- P337 + P313 - If eye irritation persists: Get medical advice or attention.

#### Storage

- : P405 - Store locked up.
- P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.

#### Disposal

- : P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

### Supplemental label elements

- : Keep container tightly closed. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Prevent dust accumulation.

### Hazards not otherwise classified

- : None known.

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 3 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 3. Composition/information on ingredients

- Substance/mixture** : Mixture  
**Other means of identification** : Not available.

Ingredient name	Other names	%	CAS number
calcium levofolinate	-	≥50 - ≤75	80433-71-2
D-mannitol	Mannitol	≥25 - ≤50	69-65-8
sodium hydroxide	-	≤0.1	1310-73-2
Hydrochloric acid	-	≤0.1	7647-01-0

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

**There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.**

## Section 4. First aid measures

### Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours. In the event of any complaints or symptoms, avoid further exposure.
- Skin contact** : Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
- Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 4 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 4. First aid measures

### Most important symptoms/effects, acute and delayed

#### Potential acute health effects

- |                     |  |
|---------------------|--|
| <b>Eye contact</b>  | : Causes serious eye irritation.   |
| <b>Inhalation</b>   | : May cause respiratory irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| <b>Skin contact</b> | : Causes skin irritation. May cause an allergic skin reaction.   |
| <b>Ingestion</b>    | : No known significant effects or critical hazards.  |

#### Over-exposure signs/symptoms

- |                     |  |
|---------------------|--|
| <b>Eye contact</b>  | : Adverse symptoms may include the following:<br>pain or irritation<br>watering<br>redness   |
| <b>Inhalation</b>   | : Adverse symptoms may include the following:<br>respiratory tract irritation<br>coughing<br>wheezing and breathing difficulties<br>asthma |
| <b>Skin contact</b> | : Adverse symptoms may include the following:<br>irritation<br>redness   |
| <b>Ingestion</b>    | : No specific data.  |

### Indication of immediate medical attention and special treatment needed, if necessary

- |                                   |   |
|-----------------------------------|---|
| <b>Notes to physician</b>         | : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.   |
| <b>Specific treatments</b>        | : No specific treatment.  |
| <b>Protection of first-aiders</b> | : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. |

See toxicological information (Section 11)

## Section 5. Fire-fighting measures

#### Extinguishing media

- |                                       |                            |
|---------------------------------------|----------------------------|
| <b>Suitable extinguishing media</b>   | : Use dry chemical powder. |
| <b>Unsuitable extinguishing media</b> | : Do not use water jet.    |

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 5 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 5. Fire-fighting measures

<b>Specific hazards arising from the chemical</b>	: May form explosive dust-air mixture if dispersed.
<b>Hazardous thermal decomposition products</b>	: Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides metal oxide/oxides
<b>Special protective actions for fire-fighters</b>	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
<b>Special protective equipment for fire-fighters</b>	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

## Section 6. Accidental release measures

### Personal precautions, protective equipment and emergency procedures

<b>For non-emergency personnel</b>	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing dust. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
<b>For emergency responders</b>	: If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
<b>Environmental precautions</b>	: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### Methods and materials for containment and cleaning up

<b>Small spill</b>	: Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Avoid dust generation. Using a vacuum with HEPA filter will reduce dust dispersal. Place spilled material in a designated, labeled waste container. Dispose of via a licensed waste disposal contractor.
<b>Large spill</b>	: Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Avoid dust generation. Do not dry sweep. Vacuum dust with equipment fitted with a HEPA filter and place in a closed, labeled waste container. Avoid creating dusty conditions and prevent wind dispersal. Dispose of via a licensed waste disposal contractor. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 6 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 7. Handling and storage

### Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems or asthma, allergies or chronic or recurrent respiratory disease should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing dust. Avoid the creation of dust when handling and avoid all possible sources of ignition (spark or flame). Prevent dust accumulation. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Electrical equipment and lighting should be protected to appropriate standards to prevent dust coming into contact with hot surfaces, sparks or other ignition sources. Take precautionary measures against electrostatic discharges. To avoid fire or explosion, dissipate static electricity during transfer by grounding and bonding containers and equipment before transferring material. Empty containers retain product residue and can be hazardous. Do not reuse container.
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
- Conditions for safe storage, including any incompatibilities** : Store between the following temperatures: 20 to 25°C (68 to 77°F). Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

## Section 8. Exposure controls/personal protection

### Control parameters

#### Occupational exposure limits

Ingredient name	Exposure limits
calcium levofolinate D-mannitol sodium hydroxide	None. None. <b>ACGIH TLV (United States, 1/2022).</b> C: 2 mg/m <sup>3</sup> <b>NIOSH REL (United States, 10/2020).</b> CEIL: 2 mg/m <sup>3</sup> <b>OSHA PEL (United States, 5/2018).</b> TWA: 2 mg/m <sup>3</sup> 8 hours. <b>ACGIH TLV (United States, 1/2022).</b> C: 2 ppm <b>NIOSH REL (United States, 10/2020).</b>
Hydrochloric acid	

<b>SDS Title:</b> Levoleucovorin for Injection Safety Data Sheet	<b>SDS Number:</b> SDS-000031	<b>Page Number:</b> Page 7 of 16
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 20, 2023	<b>Version number:</b> 3.0

## Section 8. Exposure controls/personal protection

	CEIL: 5 ppm CEIL: 7 mg/m <sup>3</sup> <b>OSHA PEL (United States, 5/2018).</b> CEIL: 5 ppm CEIL: 7 mg/m <sup>3</sup>
--	--

- Appropriate engineering controls**
- : Use only with adequate ventilation. If user operations generate dust, fumes, gas, vapor or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.
- Environmental exposure controls**
- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### Individual protection measures

- Hygiene measures**
- : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
- Eye/face protection**
- : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles. If operating conditions cause high dust concentrations to be produced, use dust goggles.
- Skin protection**
- Hand protection**
- : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
- Body protection**
- : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Other skin protection**
- : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection**
- : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 8 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### Appearance

<b>Physical state</b>	: Solid. [Cake./Powder.]
<b>Color</b>	: White to yellowish.
<b>Odor</b>	: Not available.
<b>Odor threshold</b>	: Not available.
<b>pH</b>	: 6.5 to 8.5 [Conc. (% w/w): 1.1%]
<b>Melting point</b>	: Not available.
<b>Boiling point, initial boiling point, and boiling range</b>	: Not available.
<b>Flash point</b>	: Not applicable.
<b>Evaporation rate</b>	: Not available.
<b>Flammability</b>	: Not available.
<b>Lower and upper explosion limit/flammability limit</b>	: Not applicable.
<b>Vapor pressure</b>	: Not available.
<b>Relative vapor density</b>	: Not applicable.
<b>Relative density</b>	: Not available.
<b>Density</b>	: Not available.
<b>Solubility(ies)</b>	: Not available.
<b>Partition coefficient: n-octanol/water</b>	: Not applicable.
<b>Auto-ignition temperature</b>	: Not applicable.
<b>Decomposition temperature</b>	: Not available.
<b>SADT</b>	: Not available.
<b>Viscosity</b>	: Not applicable.
<b>Flow time (ISO 2431)</b>	: Not available.
<b>Particle characteristics</b>	
<b>Median particle size</b>	: Not available.
<b>Other information</b>	
<b>Physical/chemical properties comments</b>	: No additional information.

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 9 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 10. Stability and reactivity

<b>Reactivity</b>	: No specific test data related to reactivity available for this product or its ingredients.
<b>Chemical stability</b>	: The product is stable.
<b>Possibility of hazardous reactions</b>	: Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerization will not occur.
<b>Conditions to avoid</b>	: Avoid the creation of dust when handling and avoid all possible sources of ignition (spark or flame). Take precautionary measures against electrostatic discharges. To avoid fire or explosion, dissipate static electricity during transfer by grounding and bonding containers and equipment before transferring material. Prevent dust accumulation. Protect from light.
<b>Incompatible materials</b>	: Reactive or incompatible with the following materials: oxidizing materials
<b>Hazardous decomposition products</b>	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## Section 11. Toxicological information

### Information on toxicological effects

#### Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
D-mannitol	LD50 Oral	Rat	13500 mg/kg	-

#### Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
sodium hydroxide	Eyes - Mild irritant Eyes - Severe irritant Eyes - Severe irritant Eyes - Severe irritant Skin - Severe irritant	Rabbit Rabbit Rabbit Rabbit Rabbit	- - - - -	400 ug 1 % 0.5 minutes 1 mg 24 hours 50 ug 24 hours 500 mg 0.5 minutes 5 mg	- - - - -
Hydrochloric acid	Eyes - Mild irritant	Rabbit	-		

#### Sensitization

Not available.

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 10 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 11. Toxicological information

### Mutagenicity

**Conclusion/Summary** : Not available.

### Carcinogenicity

**Conclusion/Summary** : Not available.

### Classification

Product/ingredient name	OSHA	IARC	NTP
Hydrochloric acid	-	3	-

### Reproductive toxicity

**Conclusion/Summary** : Not available.

### Teratogenicity

**Conclusion/Summary** : Not available.

### Specific target organ toxicity (single exposure)

Name	Category	Route of exposure	Target organs
calcium levofolinate	Category 3	-	Respiratory tract irritation
sodium hydroxide	Category 3	-	Respiratory tract irritation
Hydrochloric acid	Category 3	-	Respiratory tract irritation

### Specific target organ toxicity (repeated exposure)

Not available.

### Aspiration hazard

Not available.

**Information on the likely routes of exposure** : Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.

### Potential acute health effects

**Eye contact** : Causes serious eye irritation.

**Inhalation** : May cause respiratory irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Skin contact** : Causes skin irritation. May cause an allergic skin reaction.

**Ingestion** : No known significant effects or critical hazards.

### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : Adverse symptoms may include the following:  
pain or irritation  
watering  
redness

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 11 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 11. Toxicological information

- Inhalation** : Adverse symptoms may include the following:  
 respiratory tract irritation  
 coughing  
 wheezing and breathing difficulties  
 asthma
- Skin contact** : Adverse symptoms may include the following:  
 irritation  
 redness
- Ingestion** : No specific data.

### Delayed and immediate effects and also chronic effects from short and long term exposure

#### Short term exposure

- Potential immediate effects** : Not available.

- Potential delayed effects** : Not available.

#### Long term exposure

- Potential immediate effects** : Not available.

- Potential delayed effects** : Not available.

#### Potential chronic health effects

- General** : Repeated or prolonged inhalation of dust may lead to chronic respiratory irritation. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.

- Carcinogenicity** : No known significant effects or critical hazards.

- Mutagenicity** : No known significant effects or critical hazards.

- Reproductive toxicity** : No known significant effects or critical hazards.

### Numerical measures of toxicity

#### Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
D-mannitol	13500	N/A	N/A	N/A	N/A

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 12 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 12. Ecological information

### Toxicity

Product/ingredient name	Result	Species	Exposure
sodium hydroxide	Acute EC50 40.38 mg/l Fresh water	Crustaceans - Ceriodaphnia dubia - Neonate	48 hours
Hydrochloric acid	Acute LC50 125 ppm Fresh water Acute LC50 240000 µg/l Marine water	Fish - Gambusia affinis - Adult Crustaceans - Carcinus maenas - Adult	96 hours 48 hours
	Acute LC50 282 ppm Fresh water	Fish - Gambusia affinis - Adult	96 hours

**Conclusion/Summary** : Not available.

### Persistence and degradability

Not available.

### Bioaccumulative potential

Product/ingredient name	LogP <sub>ow</sub>	BCF	Potential
D-mannitol	-3.1	-	low

### Mobility in soil

**Soil/water partition coefficient (K<sub>oc</sub>)** : Not available.

**Other adverse effects** : No known significant effects or critical hazards.

## Section 13. Disposal considerations

<b>Disposal methods</b>	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.
-------------------------	--

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 13 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 14. Transport information

	DOT Classification	IMDG	IATA
<b>UN number</b>	Not regulated.	Not regulated.	Not regulated.
<b>UN proper shipping name</b>	-	-	-
<b>Transport hazard class(es)</b>	-	-	-
<b>Packing group</b>	-	-	-
<b>Environmental hazards</b>	No.	No.	No.

### Additional information

- Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.
- Transport in bulk according to IMO instruments** : Not available.

## Section 15. Regulatory information

- U.S. Federal regulations** : **TSCA 8(a) CDR Exempt/Partial exemption:** Not determined  
**United States inventory (TSCA 8b):** Not determined.  
**Clean Water Act (CWA) 311:** sodium hydroxide; Hydrochloric acid
- Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs)** : Listed
- Clean Air Act Section 602 Class I Substances** : Not listed
- Clean Air Act Section 602 Class II Substances** : Not listed
- DEA List I Chemicals (Precursor Chemicals)** : Not listed
- DEA List II Chemicals (Essential Chemicals)** : Not listed

### SARA 302/304

#### Composition/information on ingredients

<b>SDS Title:</b> Levoleucovorin for Injection Safety Data Sheet	<b>SDS Number:</b> SDS-000031	<b>Page Number:</b> Page 14 of 16
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> January 20, 2023	<b>Version number:</b> 3.0

## Section 15. Regulatory information

<b>Name</b>	<b>%</b>	<b>EHS</b>	<b>SARA 302 TPQ</b>		<b>SARA 304 RQ</b>	
			<b>(lbs)</b>	<b>(gallons)</b>	<b>(lbs)</b>	<b>(gallons)</b>
Hydrochloric acid	≤0.1	Yes.	500	50.6	5000	506.5

**SARA 304 RQ** : 5555555.6 lbs / 2522222.2 kg

### SARA 311/312

**Classification** : COMBUSTIBLE DUSTS  
SKIN IRRITATION - Category 2  
EYE IRRIGATION - Category 2A  
RESPIRATORY SENSITIZATION - Category 1  
SKIN SENSITIZATION - Category 1  
SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3

### Composition/information on ingredients

<b>Name</b>	<b>%</b>	<b>Classification</b>
calcium levofolinate	≥50 - ≤75	SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2A RESPIRATORY SENSITIZATION - Category 1 SKIN SENSITIZATION - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3
sodium hydroxide	≤0.1	CORROSIVE TO METALS - Category 1 SKIN CORROSION - Category 1A SERIOUS EYE DAMAGE - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 HNOC - Corrosive to digestive tract [severe]
Hydrochloric acid	≤0.1	SKIN CORROSION - Category 1B SERIOUS EYE DAMAGE - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 HNOC - Corrosive to digestive tract

### SARA 313

Not applicable.

### State regulations

**Massachusetts** : None of the components are listed.  
**New York** : None of the components are listed.  
**New Jersey** : None of the components are listed.  
**Pennsylvania** : None of the components are listed.

### California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

### International regulations

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 15 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 15. Regulatory information

### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

### Montreal Protocol

Not listed.

### Stockholm Convention on Persistent Organic Pollutants

Not listed.

### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

## Section 16. Other information

### Hazardous Material Information System (U.S.A.)

Health	*	2
Flammability		3
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

### National Fire Protection Association (U.S.A.)



### Procedure used to derive the classification

Classification	Justification
COMBUSTIBLE DUSTS	On basis of test data
SKIN IRRITATION - Category 2	Calculation method
EYE IRRITATION - Category 2A	Calculation method
RESPIRATORY SENSITIZATION - Category 1	Calculation method
SKIN SENSITIZATION - Category 1	Calculation method
SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3	Calculation method

SDS Title: Levoleucovorin for Injection Safety Data Sheet	SDS Number: SDS-000031	Page Number: Page 16 of 16
Function: Regulatory Affairs	Effective Date: January 20, 2023	Version number: 3.0

## Section 16. Other information

### History

Date of issue/Date of revision	: 01/20/2023
Date of previous issue	: 05/13/2022
Version	: 3.0
Prepared by	: Sphera Solutions
Key to abbreviations	: ATE = Acute Toxicity Estimate AMP = Acceptable maximum peak above the acceptable ceiling concentration for an 8-hr shift BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Intermediate Bulk Container IMDG = International Maritime Dangerous Goods LogPow = logarithm of the octanol/water partition coefficient MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) N/A = Not available UN = United Nations
References	: HCS (U.S.A.)- Hazard Communication Standard International transport regulations

► Indicates information that has changed from previously issued version.

### Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.